Polymorphisms of Drug-Metabolizing Enzymes and Transporters Contribute to the Individual Variations of Erlotinib Steady State Trough Concentration, Treatment Outcomes, and Adverse Reactions in Epidermal Growth Factor Receptor–Mutated Non-Small Cell Lung Cancer Patients

BACKGROUND: Erlotinib is presently the first line treatment for non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) active mutation. An increasing number of evidences show that the treatment efficacy and toxicities are considerably heterogeneous among individuals. Hence,...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Front Pharmacol
Hlavní autoři: Liao, Dehua, Liu, Zhigang, Zhang, Yongchang, Liu, Ni, Yao, Dunwu, Cao, Lizhi, Chen, Yun, Fu, Yilan, Yang, Nong, Xiang, Daxiong
Médium: Artigo
Jazyk:Inglês
Vydáno: Frontiers Media S.A. 2020
Témata:
Pharmacology
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7225310/
https://ncbi.nlm.nih.gov/pubmed/32457635
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2020.00664
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky